These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 160835)
1. Treatment of acute nonlymphocytic leukemia with neocarzinostatin. Griffin TW; Lister TA; Rybak ME; Rosenthal DS; Canellos GP; Woodruff R; Oliver KT Cancer Treat Rep; 1979; 63(11-12):1853-6. PubMed ID: 160835 [TBL] [Abstract][Full Text] [Related]
2. Neocarzinostatin: report of a phase II clinical trial. McKelvey EM; Murphy W; Zander A; Bodey GP Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of vindesine in patients with acute leukemia. Sklaroff RB; Arlin Z; Young CW Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Early AP; Preisler HD; Slocum H; Rustum YM Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642 [TBL] [Abstract][Full Text] [Related]
5. AMSA--a promising new agent in refractory acute leukemia. Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928 [TBL] [Abstract][Full Text] [Related]
6. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of neocarzinostatin in children with cancer. Rivera G; Howarth C; Aur RJ; Pratt CB Cancer Treat Rep; 1978 Dec; 62(12):2105-7. PubMed ID: 156067 [TBL] [Abstract][Full Text] [Related]
9. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933 [TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. Benjamin RS; Keating MJ; Valdivieso M; McCredie KB; Livingston RA; Burgess MA; Rodriguez V; Bodey GP; Gottlieb JA Cancer Treat Rep; 1979 Jun; 63(6):939-43. PubMed ID: 380802 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of neocarzinostatin in patients with acute leukemia. Van Echo DA; Wiernik PH Cancer Treat Rep; 1978 Sep; 62(9):1363-5. PubMed ID: 150945 [No Abstract] [Full Text] [Related]
13. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134 [TBL] [Abstract][Full Text] [Related]
14. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. Warrell RP; Arlin ZA; Kempin SJ; Young CW Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007 [TBL] [Abstract][Full Text] [Related]
16. Phase I and preliminary phase II study of neocarzinostatin. Griffin TW; Comis RL; Lokich JJ; Blum RH; Canellos GP Cancer Treat Rep; 1978 Dec; 62(12):2019-25. PubMed ID: 221112 [TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study. Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in adult patients with acute leukemia. Arimori S; Nagao T Tokai J Exp Clin Med; 1983 Dec; 8(5-6):411-7. PubMed ID: 6242082 [TBL] [Abstract][Full Text] [Related]
19. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637 [TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse. Kalwinsky DK; Dahl GV; Mirro J; Look AT Cancer Treat Rep; 1985; 69(7-8):887-9. PubMed ID: 4016796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]